ADDED
As of March 27, 2026, there were 97,721,696 shares of the registrant s common stock outstanding.
Exchangeable Shares and Special Voting Stock: As of March 27, 2026, there were outstanding 83,420,765 exchangeable shares of BST Sub ULC, a wholly owned subsidiary of the registrant.
The exchangeable shares are exchangeable for an equal number of the registrant s common stock, and carry rights substantially equivalent to the Company s common stock, including rights to dividends, liquidation preferences, and voting (via a Special Voting Preferred Stock held by a trustee).
All statements other than statements of historical fact contained in this Annual Report on Form 10-K are forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such as anticipate, believe, contemplate, continue, could, estimate, expect, intend, may, plan, potential, predict, project, seek, should, target, will, would, or the negative of these terms, and similar expressions or variations of such words.
Unless otherwise mentioned or unless the context requires otherwise, all references in this Annual Report on Form 10-K to the Company, we, us, our, Streamex, or similar terms refer to Streamex Corp., a Delaware corporation, and its consolidated subsidiaries.
(formerly BioSig Technologies, Inc.) ( Streamex, we, us, or the Company ) was originally formed as a Nevada corporation in February 2009 and reincorporated in Delaware in April 2011 through a merger with its wholly owned Delaware subsidiary, with the Delaware entity surviving.
On May 28, 2025, the Company completed the acquisition of Streamex Exchange Corporation ( Streamex Exchange ), a corporation incorporated under the laws of British Columbia on April 5, 2024.
The acquisition was consummated pursuant to a share purchase agreement dated May 23, 2025, as amended (the Share Purchase Agreement ).
3 The Streamex Exchange acquisition was structured through the issuance of exchangeable shares by the Company s wholly owned British Columbia unlimited liability company subsidiary ( ExchangeCo ).
REMOVED
For purposes of this computation, all officers, directors, and 5 percent beneficial owners of the registrant are deemed to be affiliates.
Such determination should not be deemed an admission that such directors, officers, or 5 percent beneficial owners are, in fact, affiliates of the registrant.
As of April 14, 2025, there were 24,252,482 shares of the registrant s common stock outstanding.
Additionally, statements concerning future matters are forward-looking statements.
Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading Risk Factors below, as well as those discussed elsewhere in this Annual Report on Form 10-K.
Unless the context indicates otherwise, references in this Annual Report to BioSig, the Company, we, our and us mean BioSig Technologies, Inc., and its predecessor entities.
BioSig is principally devoted to improving the standard of care in electrophysiology, or EP, with our PURE EP System s enhanced signal acquisition, digital signal processing, and analysis during catheter ablation of cardiac arrhythmias.
The Company has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprise in early commercialization stage.
On November 7, 2018, we formed a subsidiary under the laws of the State of Delaware, originally under the name of NeuroClear Technologies, Inc., for the purpose of pursuing additional applications of the PURE EP signal processing technology outside of the field of cardiac electrophysiology.
In March 2020, it was renamed ViralClear Pharmaceuticals, Inc.